CN111225671A - 一种选择性孕酮受体调节剂的晶体及其制备方法 - Google Patents
一种选择性孕酮受体调节剂的晶体及其制备方法 Download PDFInfo
- Publication number
- CN111225671A CN111225671A CN201880067056.5A CN201880067056A CN111225671A CN 111225671 A CN111225671 A CN 111225671A CN 201880067056 A CN201880067056 A CN 201880067056A CN 111225671 A CN111225671 A CN 111225671A
- Authority
- CN
- China
- Prior art keywords
- crystalline form
- degrees
- bay
- solvent
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本发明涉及化合物(I)的晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备含孕酮受体调节剂和治疗子宫肌瘤和/或子宫内膜异位药物制剂中的用途。本发明提供的化合物(I)的晶型比现有技术具有一种或多种改进的特性，对未来该药物的优化和开发具有重要价值。
Description
PCT国内申请，说明书已公开。
Claims (14)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711022041 | 2017-10-26 | ||
| CN2017110220410 | 2017-10-26 | ||
| CN201810078734X | 2018-01-26 | ||
| CN201810078734 | 2018-01-26 | ||
| PCT/CN2018/111270 WO2019080811A1 (zh) | 2017-10-26 | 2018-10-22 | 一种选择性孕酮受体调节剂的晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111225671A true CN111225671A (zh) | 2020-06-02 |
Family
ID=66246776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880067056.5A Pending CN111225671A (zh) | 2017-10-26 | 2018-10-22 | 一种选择性孕酮受体调节剂的晶体及其制备方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210171568A1 (zh) |
| EP (1) | EP3701951A4 (zh) |
| JP (1) | JP2021500359A (zh) |
| CN (1) | CN111225671A (zh) |
| WO (1) | WO2019080811A1 (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080085875A1 (en) * | 2006-06-02 | 2008-04-10 | Wolfgang Beckmann | Crystalline forms of 11ss-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17a-pregna-4,9-dien-3-one |
| CN102482317A (zh) * | 2009-07-20 | 2012-05-30 | 拜耳医药股份有限公司 | 17-羟基-17-五氟乙基-雌-4,9(10)-二烯-11-芳基衍生物、其制备方法及其用于治疗疾病的用途 |
| WO2016184863A1 (en) * | 2015-05-18 | 2016-11-24 | Bayer Pharma Aktiengesellschaft | Selective progesterone receptor modulator (sprm) regimen |
-
2018
- 2018-10-22 JP JP2020522371A patent/JP2021500359A/ja active Pending
- 2018-10-22 CN CN201880067056.5A patent/CN111225671A/zh active Pending
- 2018-10-22 US US16/759,066 patent/US20210171568A1/en not_active Abandoned
- 2018-10-22 WO PCT/CN2018/111270 patent/WO2019080811A1/zh unknown
- 2018-10-22 EP EP18869512.6A patent/EP3701951A4/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080085875A1 (en) * | 2006-06-02 | 2008-04-10 | Wolfgang Beckmann | Crystalline forms of 11ss-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17a-pregna-4,9-dien-3-one |
| CN102482317A (zh) * | 2009-07-20 | 2012-05-30 | 拜耳医药股份有限公司 | 17-羟基-17-五氟乙基-雌-4,9(10)-二烯-11-芳基衍生物、其制备方法及其用于治疗疾病的用途 |
| WO2016184863A1 (en) * | 2015-05-18 | 2016-11-24 | Bayer Pharma Aktiengesellschaft | Selective progesterone receptor modulator (sprm) regimen |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3701951A1 (en) | 2020-09-02 |
| EP3701951A4 (en) | 2020-09-16 |
| JP2021500359A (ja) | 2021-01-07 |
| US20210171568A1 (en) | 2021-06-10 |
| WO2019080811A1 (zh) | 2019-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110494423B (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
| EP3549932B1 (en) | Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof | |
| CN114957157A (zh) | 奥扎莫德盐酸盐的晶型及其制备方法 | |
| WO2017107972A1 (zh) | 一种选择性s1p1受体激动剂的新晶型及其制备方法 | |
| CN111344283B (zh) | Arn-509的晶型及其制备方法和用途 | |
| CN112047893B (zh) | 吉非替尼与水杨酸共晶体 | |
| CN110128356A (zh) | 一种吉非替尼与3-羟基苯甲酸共晶体 | |
| CN108137516A (zh) | 奥扎莫德的晶型、其制备方法及药物组合物 | |
| WO2023040513A1 (zh) | Amg510化合物的晶型及其制备方法和用途 | |
| WO2019042219A1 (zh) | 奥扎莫德盐酸盐的晶型及其制备方法 | |
| WO2022122014A1 (zh) | Lanifibranor的晶型及其制备方法和用途 | |
| CN114773342A (zh) | Mrtx849化合物的晶型及其制备方法和用途 | |
| WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
| CN111225671A (zh) | 一种选择性孕酮受体调节剂的晶体及其制备方法 | |
| WO2019210511A1 (zh) | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 | |
| CN110291071B (zh) | Sb-939的盐的晶型及其制备方法和用途 | |
| CN108727417B (zh) | 多环化合物钠盐及其多晶型、制备方法及应用 | |
| CN110036003A (zh) | Ap26113的新晶型及其制备方法 | |
| WO2015180681A1 (zh) | 一种环肽类化合物的组合物及其制备方法和用途 | |
| CN110730785B (zh) | 一种脂肪酸胆汁酸偶合物的晶型及其制备方法和用途 | |
| CN114630668B (zh) | 一种Aprocitentan晶型及其制备方法和用途 | |
| US11999750B2 (en) | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide | |
| WO2024022275A1 (zh) | Xevinapant的晶型及其制备方法和用途 | |
| WO2019105388A1 (zh) | 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途 | |
| CN116410165A (zh) | 一种淫羊藿素与尿素共晶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200602 |
|
| WD01 | Invention patent application deemed withdrawn after publication |